Business Context and Reporting Period
This Form 8-K is filed by Angion Biomedica Corp. (not Elicio Therapeutics, Inc., as noted in the metadata request) on August 12, 2021. The report announces financial results for the fiscal quarter ended June 30, 2021. The company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol ANGN.
Key Financial Metrics
The filing text itself does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the text provided. It serves solely as a notification that the results for the quarter ended June 30, 2021, have been issued via a press release.
Guidance, Outlook, and Risks
The document does not contain specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information furnished, including the referenced press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated August 12, 2021), as they are not listed in this summary text.
- Confirm the company name is Angion Biomedica Corp., noting the discrepancy with the "Elicio Therapeutics" label in the request metadata.
- Review the full press release for any forward-looking statements or operational updates not captured in this brief notification.
- Check the company's status as an emerging growth company for potential differences in financial reporting standards.